Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy
- PMID:9129561
- DOI: 10.1016/S0009-9236(97)90194-6
Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy
Abstract
Objective: To investigate the pharmacokinetics of the four stereoisomers of valnoctamide, a mild tranquilizer endowed with anticonvulsant properties.
Methods: Racemic valnoctamide, 400 mg, was administered orally to seven healthy subjects and to six patients with epilepsy stabilized with long-term carbamazepine therapy. In the patients with epilepsy, valnoctamide kinetics was also reassessed after 8-day oral dosing at a dosage of 600 mg daily. Plasma samples were assayed by gas chromatography-mass spectrometry with use of a capillary column coated with chiral stationary phase that enabled baseline resolution of the four stereoisomers, designated hereafter as A, B, C, and D (where A and C, together with B and D, represent enantiomeric pairs).
Results: In healthy subjects, stereoisomers A, C, and D showed similar kinetics, with an apparent oral clearance (CL/F) of about 4 1/2 L/hr, a half-life (t1/2) of about 10 hours, and an apparent volume of distribution (VSS/F) of about 65 L. However, stereoisomer B showed a much higher clearance (8.7 +/- 0.9 L/hr) and a shorter t1/2 (5.8 hours). For all stereoisomers, CL/F values in patients with epilepsy were about tenfold higher than those found in healthy subjects. Compared with healthy subjects, patients with epilepsy also showed shorter t1/2 values and higher VSS/F values for each of the stereoisomers. After 7-day dosing, CL/F values at steady state were lower than those determined in the same patients after a single dose.
Conclusions: Valnoctamide exhibits enantioselectivity and diastereoselectivity, an observation that may have important practical implications if pharmacodynamic differences between stereoisomers are also found. The observed pharmacokinetic differences between healthy subjects and patients with epilepsy are likely to be related to induction of metabolism of valnoctamide stereoisomers by carbamazepine.
Similar articles
- Pharmacokinetic-pharmacodynamic relationships of (2S,3S)-valnoctamide and its stereoisomer (2R,3S)-valnoctamide in rodent models of epilepsy.Isoherranen N, White HS, Klein BD, Roeder M, Woodhead JH, Schurig V, Yagen B, Bialer M.Isoherranen N, et al.Pharm Res. 2003 Aug;20(8):1293-301. doi: 10.1023/a:1025069519218.Pharm Res. 2003.PMID:12948028
- Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.Zhao RK, Cheng G, Tang J, Song J, Peng WX.Zhao RK, et al.Clin Ther. 2009 May;31(5):1022-36. doi: 10.1016/j.clinthera.2009.05.005.Clin Ther. 2009.PMID:19539103Clinical Trial.
- Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.Perucca E, Cloyd J, Critchley D, Fuseau E.Perucca E, et al.Epilepsia. 2008 Jul;49(7):1123-41. doi: 10.1111/j.1528-1167.2008.01665.x.Epilepsia. 2008.PMID:18503564
- The potential of sec-butylpropylacetamide (SPD) and valnoctamide and their individual stereoisomers in status epilepticus.Shekh-Ahmad T, Mawasi H, McDonough JH, Yagen B, Bialer M.Shekh-Ahmad T, et al.Epilepsy Behav. 2015 Aug;49:298-302. doi: 10.1016/j.yebeh.2015.04.012. Epub 2015 May 13.Epilepsy Behav. 2015.PMID:25979572Review.
- Stereochemistry in pharmacotherapy: when mirror images are not identical.Tracy TS.Tracy TS.Ann Pharmacother. 1995 Feb;29(2):161-5. doi: 10.1177/106002809502900211.Ann Pharmacother. 1995.PMID:7756715Review.
Cited by
- Pharmacokinetic-pharmacodynamic relationships of (2S,3S)-valnoctamide and its stereoisomer (2R,3S)-valnoctamide in rodent models of epilepsy.Isoherranen N, White HS, Klein BD, Roeder M, Woodhead JH, Schurig V, Yagen B, Bialer M.Isoherranen N, et al.Pharm Res. 2003 Aug;20(8):1293-301. doi: 10.1023/a:1025069519218.Pharm Res. 2003.PMID:12948028
- Stereoselective pharmacokinetics and pharmacodynamics of propylisopropyl acetamide, a CNS-active chiral amide analog of valproic acid.Spiegelstein O, Yagen B, Levy RH, Finnell RH, Bennett GD, Roeder M, Schurig V, Bialer M.Spiegelstein O, et al.Pharm Res. 1999 Oct;16(10):1582-8. doi: 10.1023/a:1018960722284.Pharm Res. 1999.PMID:10554101
- Diverse mechanisms of antiepileptic drugs in the development pipeline.Rogawski MA.Rogawski MA.Epilepsy Res. 2006 Jun;69(3):273-94. doi: 10.1016/j.eplepsyres.2006.02.004. Epub 2006 Apr 18.Epilepsy Res. 2006.PMID:16621450Free PMC article.Review.
- Valproic Acid: second generation.Bialer M, Yagen B.Bialer M, et al.Neurotherapeutics. 2007 Jan;4(1):130-7. doi: 10.1016/j.nurt.2006.11.007.Neurotherapeutics. 2007.PMID:17199028Free PMC article.Review.
- Valnoctamide and sec-butyl-propylacetamide (SPD) for acute seizures and status epilepticus.Shekh-Ahmad T, Hen N, McDonough JH, Yagen B, Bialer M.Shekh-Ahmad T, et al.Epilepsia. 2013 Sep;54 Suppl 6(Suppl 6):99-102. doi: 10.1111/epi.12290.Epilepsia. 2013.PMID:24001086Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous